Apples and oranges

BJU International

Volumn 97, Issue 3, 2006, Pages 435-438

  Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GONADORELIN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR EFFECT; CASTRATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG WITHDRAWAL; EARLY CANCER; ESTHETICS; GYNECOMASTIA; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MASTALGIA; MUTATION; NOTE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOLOGICAL ASPECT; RESPIRATORY FUNCTION; SIDE EFFECT; STANDARD; URETER OBSTRUCTION; DISEASE COURSE; DISEASE FREE SURVIVAL; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; STATISTICAL ANALYSIS; SURVIVAL;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33645012749     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06088.x     Document Type: Note

References (34)

1. McLeod DG Iversen P See WA Morris T Armstrong J Wirth MP Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 2006 97 247 54
2. Wirth M Tyrell C Wallace M et al. Bicalutamide ('Casodex') 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression Urology 2001 58 146 51
3. See WA Wirth MP McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program J Urol 2002 168 429 35
4. Wirth MP See WA McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer Program at median followup of 5.4 years J Urol 2004 172 1865 70
5. Iversen P Johansson JE Lodding P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 2004 172 1871 6
6. Iversen P McLeod D See W Morris T Armstrong J Wirth M Adding bicalutamide 150 mg to standard care for localised or locally advanced prostate cancer: results from the largest hormonal therapy trial ever conducted in prostate cancer patients, at over 7 years follow up Eur J Cancer Suppl 2005 3 1 (Abstract)
7. Tyrrell CJ Payne H See WA et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme Radiother Oncol 2005 76 4 10
8. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate Surg Gynecol Obstet 1967 124 1011 7
9. Bolla M Collette L Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 2002 360 103 6
10. Lawton CA Winter K Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 49 937 46
11. Pilepich MV Winter K Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 2005 61 1285 90
12. Pilepich MV Winter K John MJ et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 50 1243 52
13. Hanks GE Pajak TF Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 2003 21 3972 8
14. D'Amico AV Manola J Loffredo M Renshaw AA DellaCroce A Kantoff PW 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 2004 292 821 7
15. Nair B Wilt T MacDonald R Rutks I Early versus deferred androgen suppression in the treatment of advanced prostatic cancer Cochrane Database Syst Rev 2002 1 CD003506
16. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial Br J Urol 1997 79 235 46
17. Messing EM Manola J Sarosdy M Wilding G Crawford ED Trump D Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 1999 341 1781 8
18. Byar DP Proceedings: The Veteran Administration Cooperative Urological Research Group's studies of cancer of the prostate Cancer 1973 32 1126 30
19. Kirk D Immediate vs deferred hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 2000 86 Suppl. 3 S220
20. Studer UE Hauri D Hanselmann S et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 J Clin Oncol 2004 22 4109 18
21. Studer UE Whelan P Albrecht W et al. Patients with asymptomatic prostate cancer T0-4 N0-2 not suitable for local definitive treatment: do they need immediate androgen deprivation? Eur Urol Suppl 2005 4 78
22. Bales GT Chodak GW A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer Urology 1996 47 Suppl. 1A 38 43
23. Tyrrell CJ Kaisary AV Iversen P et al. Randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 1998 33 447 56
24. Debes JD Tindall DJ Mechanisms of androgen-refractory prostate cancer N Engl J Med 2004 351 1488 90
25. Chen CD Welsbie DS Tran C et al. Molecular determinants of resistance to antiandrogen therapy Nat Med 2004 10 33 9
26. Culig Z Hoffmann J Erdel M et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system Br J Cancer 1999 81 242 51
27. Hobisch A Fritzer A Comuzzi B et al. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide Prostate 2005 DOI: 10.1002/pros.20365
28. Bohl CE Gao W Miller DD Bell CE Dalton JT Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc Natl Acad Sci USA 2005 102 6201 6
29. Kattan MW Scardino PT Prediction of progression: nomograms of clinical utility Clin Prostate Cancer 2002 1 90 6
30. Kattan MW Eastham J Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer Clin Prostate Cancer 2003 1 221 6
31. Kattan MW Zelefsky MJ Kupelian PA et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer J Clin Oncol 2003 21 4568 71
32. Sengupta S Myers RP Slezak JM Bergstralh EJ Zincke H Blute ML Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy J Urol 2005 174 2191 6
33. Lin DD Schultz D Renshaw AA Rubin MA Richie JP D'Amico AV Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era Urology 2005 65 528 32
34. Abrahamsson PA Anderson J Boccon-Gibod L Schulman C Studer UE Wirth M Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer Eur Urol 2005 48 900 5